Commercial, Reimbursement Hurdles Need To Be Addressed By Antimicrobial Resistance Efforts

Melinta describes difficulties launching its new antibiotics at BIO CEO & Investor Conference; companies and other stakeholders urge Congress to enact package of incentives to reinvigorate antibiotic pipeline.

Superbug strain bacteria concept as a killer microbe shaped as a death skull face as a symbol for MRSA medical healthcare risk and antimicrobial health hazard as a 3D illustration on white. - Illustration

US FDA Commissioner Scott Gottlieb’s proposal for a subscription model for hospital purchasing of antibiotics could help shore up the market, but industry experts think additional incentives are needed.

Reimbursement for antibiotics, particularly at hospitals, is among the factors limiting the antibiotic market and holding

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

More from Pink Sheet